ECMO in COVID-19-prolonged therapy needed? A retrospective analysis of outcome and prognostic factors.
Esther DreierMaximilian Valentin MalfertheinerThomas DienemannChristoph FisserMaik FoltanFlorian GeismannBernhard GrafDirk LunzLars Siegfried MaierThomas MüllerRobert OffnerDavid PeterhoffAlois PhilippBernd SalzbergerBarbara SchmidtBarbara SinnerMatthias LubnowPublished in: Perfusion (2021)
VV ECMO support for COVID-19-induced ARDS is justified if initiated early and at an experienced ECMO center. Prolonged ECMO therapy might be required in those patients. Although no relevant predictive factors for the duration of ECMO support were found, the decision to stop therapy should not be made dependent of the length of ECMO treatment.
Keyphrases
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- prognostic factors
- respiratory failure
- coronavirus disease
- mechanical ventilation
- sars cov
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- stem cells
- high glucose
- respiratory syndrome coronavirus
- endothelial cells
- diabetic rats
- bone marrow
- oxidative stress
- drug induced